Tetraphase Pharmaceuticals Inc., of Watertown, Mass., said it dosed the first patient in IGNITE4, its new phase III trial evaluating the efficacy and safety of intravenous (I.V.) eravacycline compared to meropenem in complicated intra-abdominal infections (cIAIs).